Casi Pharmaceuticals Stock Performance
| CASI Stock | USD 0.78 0.03 4.00% |
The firm shows a Beta (market volatility) of 1.76, which signifies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, CASI Pharmaceuticals will likely underperform. At this point, CASI Pharmaceuticals has a negative expected return of -0.66%. Please make sure to confirm CASI Pharmaceuticals' skewness, as well as the relationship between the rate of daily change and price action indicator , to decide if CASI Pharmaceuticals performance from the past will be repeated in the future.
Risk-Adjusted Performance
Weakest
Weak | Strong |
Over the last 90 days CASI Pharmaceuticals has generated negative risk-adjusted returns adding no value to investors with long positions. Despite unsteady performance in the last few months, the Stock's basic indicators remain fairly strong which may send shares a bit higher in January 2026. The recent confusion may also be a sign of long-lasting up-swing for the firm traders. ...more
Last Split Factor 1:10 | Last Split Date 2022-06-02 |
1 | Disposition of 370370 shares by Wealth Strategy Holding Ltd of CASI Pharmaceuticals at 3.69 subject to Rule 16b-3 | 10/02/2025 |
2 | CASI Pharmaceuticals Inc. stock momentum explained - Dip Buying Verified Momentum Stock Watchlist - newser.com | 10/16/2025 |
3 | CASI Pharmaceuticals Announces Upcoming Presentation of Clinical Results for CID-103 at the 67th American Society of Hematology Annual Meeting | 11/03/2025 |
4 | CASI Pharmaceuticals appeals NASDAQ delisting determination | 11/10/2025 |
5 | PRI-CASI Sustainability Forum for COP30 concluded in Brazil | 11/12/2025 |
6 | CASI Pharmaceuticals Announces Changes in Board Governance | 11/19/2025 |
7 | Lacklustre Performance Is Driving CASI Pharmaceuticals, Inc.s 27 percent Price Drop | 11/25/2025 |
8 | CASI Pharmaceuticals Announces Results from CID-103 Immune Thrombocytopenia Study at the 67th American Society of Hematology Annual Meeting | 12/08/2025 |
9 | CASI Pharmaceuticals Announces Up to 20 Million Convertible Note Financing | 12/11/2025 |
10 | Why CASI Pharmaceuticals Inc. stock could rally in 2025 - 2025 Market WrapUp Safe Entry Trade Reports - DonanmHaber | 12/19/2025 |
11 | CASI Pharmaceuticals Receives Extension from Nasdaq to Meet Listing Requirements | 12/23/2025 |
| Begin Period Cash Flow | 17.1 M | |
| Total Cashflows From Investing Activities | 11.2 M |
CASI Pharmaceuticals Relative Risk vs. Return Landscape
If you would invest 131.00 in CASI Pharmaceuticals on September 26, 2025 and sell it today you would lose (53.00) from holding CASI Pharmaceuticals or give up 40.46% of portfolio value over 90 days. CASI Pharmaceuticals is currently does not generate positive expected returns and assumes 5.5976% risk (volatility on return distribution) over the 90 days horizon. In different words, 50% of stocks are less volatile than CASI, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
CASI Pharmaceuticals Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for CASI Pharmaceuticals' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as CASI Pharmaceuticals, and traders can use it to determine the average amount a CASI Pharmaceuticals' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.118
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | CASI |
Based on monthly moving average CASI Pharmaceuticals is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of CASI Pharmaceuticals by adding CASI Pharmaceuticals to a well-diversified portfolio.
CASI Pharmaceuticals Fundamentals Growth
CASI Stock prices reflect investors' perceptions of the future prospects and financial health of CASI Pharmaceuticals, and CASI Pharmaceuticals fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on CASI Stock performance.
| Return On Equity | -10.94 | ||||
| Return On Asset | -0.62 | ||||
| Profit Margin | (1.84) % | ||||
| Operating Margin | (3.33) % | ||||
| Current Valuation | 29.65 M | ||||
| Shares Outstanding | 15.49 M | ||||
| Price To Earning | (16.46) X | ||||
| Price To Book | 11.21 X | ||||
| Price To Sales | 0.45 X | ||||
| Revenue | 28.54 M | ||||
| Gross Profit | 9.61 M | ||||
| EBITDA | (34.87 M) | ||||
| Net Income | (39.26 M) | ||||
| Cash And Equivalents | 24.57 M | ||||
| Cash Per Share | 1.81 X | ||||
| Total Debt | 22.14 M | ||||
| Debt To Equity | 0.03 % | ||||
| Current Ratio | 3.21 X | ||||
| Book Value Per Share | (1.39) X | ||||
| Cash Flow From Operations | (29.22 M) | ||||
| Earnings Per Share | (3.02) X | ||||
| Market Capitalization | 12.12 M | ||||
| Total Asset | 53.67 M | ||||
| Retained Earnings | (700.08 M) | ||||
| Working Capital | 3.12 M | ||||
| Current Asset | 17.15 M | ||||
| Current Liabilities | 3.51 M | ||||
About CASI Pharmaceuticals Performance
By evaluating CASI Pharmaceuticals' fundamental ratios, stakeholders can gain valuable insights into CASI Pharmaceuticals' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if CASI Pharmaceuticals has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if CASI Pharmaceuticals has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 110.23 | 144.18 | |
| Return On Tangible Assets | (0.73) | (0.77) | |
| Return On Capital Employed | (2.30) | (2.19) | |
| Return On Assets | (0.73) | (0.77) | |
| Return On Equity | (21.21) | (20.15) |
Things to note about CASI Pharmaceuticals performance evaluation
Checking the ongoing alerts about CASI Pharmaceuticals for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for CASI Pharmaceuticals help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| CASI Pharmaceuticals generated a negative expected return over the last 90 days | |
| CASI Pharmaceuticals has high historical volatility and very poor performance | |
| CASI Pharmaceuticals has some characteristics of a very speculative penny stock | |
| CASI Pharmaceuticals has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 28.54 M. Net Loss for the year was (39.26 M) with profit before overhead, payroll, taxes, and interest of 9.61 M. | |
| CASI Pharmaceuticals currently holds about 24.57 M in cash with (29.22 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.81, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| CASI Pharmaceuticals has a frail financial position based on the latest SEC disclosures | |
| Roughly 39.0% of the company shares are held by company insiders | |
| Latest headline from finance.yahoo.com: CASI Pharmaceuticals Receives Extension from Nasdaq to Meet Listing Requirements |
- Analyzing CASI Pharmaceuticals' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether CASI Pharmaceuticals' stock is overvalued or undervalued compared to its peers.
- Examining CASI Pharmaceuticals' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating CASI Pharmaceuticals' management team can have a significant impact on its success or failure. Reviewing the track record and experience of CASI Pharmaceuticals' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of CASI Pharmaceuticals' stock. These opinions can provide insight into CASI Pharmaceuticals' potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for CASI Stock analysis
When running CASI Pharmaceuticals' price analysis, check to measure CASI Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy CASI Pharmaceuticals is operating at the current time. Most of CASI Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of CASI Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move CASI Pharmaceuticals' price. Additionally, you may evaluate how the addition of CASI Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume |